[{"address1": "Dr. Neergaards Vej", "address2": "5th Floor", "city": "Horsholm", "zip": "2970", "country": "Denmark", "phone": "45 31 31 97 53", "website": "https://www.evaxion-biotech.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.", "fullTimeEmployees": 49, "companyOfficers": [{"maxAge": 1, "name": "Mr. Christian  Kanstrup M.Sc.", "age": 51, "title": "Chief Executive Officer", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 373000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andreas Holm Mattsson", "age": 47, "title": "Co-Founder and Chief AI & Culture Officer", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 246000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jesper Nyegaard Nissen M.Sc.", "age": 53, "title": "Interim CFO & COO", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 296000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Birgitte  Rono Ph.D.", "age": 46, "title": "Chief Scientific Officer", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 269000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. J\u00fcrgen  Langh\u00e4rig EMBA, Ph.D.", "title": "Head of Business Development & Member of Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.97, "open": 2.9494, "dayLow": 2.7817, "dayHigh": 3.0036, "regularMarketPreviousClose": 2.97, "regularMarketOpen": 2.9494, "regularMarketDayLow": 2.7817, "regularMarketDayHigh": 3.0036, "beta": -0.257, "forwardPE": -2.0656934, "volume": 11332, "regularMarketVolume": 11332, "averageVolume": 35846, "averageVolume10days": 81380, "averageDailyVolume10Day": 81380, "marketCap": 15780249, "fiftyTwoWeekLow": 2.26, "fiftyTwoWeekHigh": 13.61, "priceToSalesTrailing12Months": 56.763485, "fiftyDayAverage": 2.97452, "twoHundredDayAverage": 4.040205, "currency": "USD", "enterpriseValue": 155628864, "floatShares": 35137227, "sharesOutstanding": 5576060, "sharesShort": 34120, "sharesShortPriorMonth": 41540, "sharesShortPreviousMonthDate": 1722384000, "dateShortInterest": 1724976000, "sharesPercentSharesOut": 0.0061000003, "heldPercentInsiders": 0.15525, "heldPercentInstitutions": 0.08257, "shortRatio": 1.26, "shortPercentOfFloat": 0.0086, "impliedSharesOutstanding": 37907000, "bookValue": 0.232, "priceToBook": 12.198276, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -15205000, "trailingEps": -4.5, "forwardEps": -1.37, "lastSplitFactor": "1:10", "lastSplitDate": 1705881600, "enterpriseToRevenue": 559.816, "enterpriseToEbitda": -8.276, "52WeekChange": -0.6670588, "SandP52WeekChange": 0.33085096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "EVAX", "underlyingSymbol": "EVAX", "shortName": "Evaxion Biotech A/S", "longName": "Evaxion Biotech A/S", "firstTradeDateEpochUtc": 1612535400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "10e58503-7bd5-32f9-974e-d651a4f9f505", "messageBoardId": "finmb_319014926", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.83, "targetHighPrice": 18.0, "targetLowPrice": 7.0, "targetMeanPrice": 10.85, "targetMedianPrice": 8.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 7993000, "totalCashPerShare": 0.148, "ebitda": -18804000, "totalDebt": 10489000, "quickRatio": 2.299, "currentRatio": 2.8, "totalRevenue": 278000, "debtToEquity": 837.111, "revenuePerShare": 0.069, "returnOnAssets": -0.74656, "returnOnEquity": -8.02798, "freeCashflow": -10472125, "operatingCashflow": -15382000, "grossMargins": 1.0, "operatingMargins": -29.74675, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-26"}]